Black Rock Inc. Allogene Therapeutics, Inc. Call Options Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALLO
# of Institutions
173Shares Held
132MCall Options Held
94.3KPut Options Held
112K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$56.1 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$24.6 Million0.0% of portfolio
-
State Street Corp Boston, MA7.67MShares$23 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$20.7 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.79MShares$17.4 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $431M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...